Molecular Basis and Gene Therapies of Cystic Fibrosis

Summary of Genes. Thirty years ago, the gene responsible for cystic fibrosis (CF), a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, was identified. This progress has considerably changed our understanding of the pathophysiology of CF an...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (210 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545443304498
ctrlnum (CKB)5400000000041976
(oapen)https://directory.doabooks.org/handle/20.500.12854/69404
(EXLCZ)995400000000041976
collection bib_alma
record_format marc
spelling Engelhardt, John edt
Molecular Basis and Gene Therapies of Cystic Fibrosis
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
1 electronic resource (210 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Summary of Genes. Thirty years ago, the gene responsible for cystic fibrosis (CF), a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, was identified. This progress has considerably changed our understanding of the pathophysiology of CF and has paved the way for the development of novel and specific therapies for the disease. The CFTR gene contains 27 exons and is characterized by a frequent three base pair deletion of the p.Phe508del. As a result of collaborative work, today more than 2000 mutations have been reported in the gene, and their impact on protein function is now more evident and useful in designing new strategies to correct the gene defect. The field of gene therapy, as illustrated by Ziying Yan in this book, has worked on identifying an efficient vector system for the delivery of the wild-type CFTR gene to the lung. At the same time, animal models have been developed in mice, rats, rabbits, zebrafish, ferrets, and pigs to establish the efficacity of gene delivery. These animals are also of the utmost importance in testing new molecules as modulators or correctors to improve the CFTR lung function. During the last three decades, the epidemiology of CF has dramatically changed, as today cystic fibrosis is now a chronic adult pulmonary disease.
English
Medicine bicssc
cystic fibrosis
Staphylococcus aureus
superantigen
enterotoxin gene cluster
MRSA
exosomes
microvesicles
lung
primary cells
newborn screening
trypsinogen
CFTR gene
next generation sequencing
health policy
rAAV2/HBoV1
baculovirus
insect cells
lung microbiome
metagenomics
gut–lung axis
Cystic fibrosis
CFTR
transcriptomics
proteostasis
small molecules
drug development
common and new pathogenic variants
ethnic Russian population
gene therapy
cyclophosphamide
transient immunosuppression
incidence
survival
genotype-phenotype correlations
health policies
CFTR modulators
human nasal epithelial cells
organoids
biomarker
functional assay
pre-clinical in vitro models
CFTR-related disorders
molecular diagnosis
CFTR variants
Next Generation Sequencing (NGS)
disease liability
interpretation
penetrance
genotype-guided therapy
miRNA
airway basal cell
lentivirus
3-03943-683-X
3-03943-684-8
Ferec, Claude edt
Yan, Ziying edt
Engelhardt, John oth
Ferec, Claude oth
Yan, Ziying oth
language English
format eBook
author2 Ferec, Claude
Yan, Ziying
Engelhardt, John
Ferec, Claude
Yan, Ziying
author_facet Ferec, Claude
Yan, Ziying
Engelhardt, John
Ferec, Claude
Yan, Ziying
author2_variant j e je
c f cf
z y zy
author2_role HerausgeberIn
HerausgeberIn
Sonstige
Sonstige
Sonstige
title Molecular Basis and Gene Therapies of Cystic Fibrosis
spellingShingle Molecular Basis and Gene Therapies of Cystic Fibrosis
title_full Molecular Basis and Gene Therapies of Cystic Fibrosis
title_fullStr Molecular Basis and Gene Therapies of Cystic Fibrosis
title_full_unstemmed Molecular Basis and Gene Therapies of Cystic Fibrosis
title_auth Molecular Basis and Gene Therapies of Cystic Fibrosis
title_new Molecular Basis and Gene Therapies of Cystic Fibrosis
title_sort molecular basis and gene therapies of cystic fibrosis
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2020
physical 1 electronic resource (210 p.)
isbn 3-03943-683-X
3-03943-684-8
illustrated Not Illustrated
work_keys_str_mv AT engelhardtjohn molecularbasisandgenetherapiesofcysticfibrosis
AT ferecclaude molecularbasisandgenetherapiesofcysticfibrosis
AT yanziying molecularbasisandgenetherapiesofcysticfibrosis
status_str n
ids_txt_mv (CKB)5400000000041976
(oapen)https://directory.doabooks.org/handle/20.500.12854/69404
(EXLCZ)995400000000041976
carrierType_str_mv cr
is_hierarchy_title Molecular Basis and Gene Therapies of Cystic Fibrosis
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
noLinkedField
noLinkedField
_version_ 1796652245964554241
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04071nam-a2200961z--4500</leader><controlfield tag="001">993545443304498</controlfield><controlfield tag="005">20231214133526.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041976</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041976</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Engelhardt, John</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular Basis and Gene Therapies of Cystic Fibrosis</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (210 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary of Genes. Thirty years ago, the gene responsible for cystic fibrosis (CF), a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, was identified. This progress has considerably changed our understanding of the pathophysiology of CF and has paved the way for the development of novel and specific therapies for the disease. The CFTR gene contains 27 exons and is characterized by a frequent three base pair deletion of the p.Phe508del. As a result of collaborative work, today more than 2000 mutations have been reported in the gene, and their impact on protein function is now more evident and useful in designing new strategies to correct the gene defect. The field of gene therapy, as illustrated by Ziying Yan in this book, has worked on identifying an efficient vector system for the delivery of the wild-type CFTR gene to the lung. At the same time, animal models have been developed in mice, rats, rabbits, zebrafish, ferrets, and pigs to establish the efficacity of gene delivery. These animals are also of the utmost importance in testing new molecules as modulators or correctors to improve the CFTR lung function. During the last three decades, the epidemiology of CF has dramatically changed, as today cystic fibrosis is now a chronic adult pulmonary disease.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cystic fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Staphylococcus aureus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">superantigen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enterotoxin gene cluster</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MRSA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exosomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microvesicles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">primary cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">newborn screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">trypsinogen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFTR gene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">next generation sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">health policy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rAAV2/HBoV1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">baculovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">insect cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung microbiome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metagenomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gut–lung axis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cystic fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFTR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proteostasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">small molecules</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">common and new pathogenic variants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ethnic Russian population</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclophosphamide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transient immunosuppression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">incidence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genotype-phenotype correlations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">health policies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFTR modulators</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human nasal epithelial cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">organoids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">functional assay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pre-clinical in vitro models</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFTR-related disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFTR variants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Next Generation Sequencing (NGS)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disease liability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interpretation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">penetrance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genotype-guided therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">airway basal cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lentivirus</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-683-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-684-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferec, Claude</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yan, Ziying</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Engelhardt, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferec, Claude</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yan, Ziying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:56:43 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337965580004498&amp;Force_direct=true</subfield><subfield code="Z">5337965580004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337965580004498</subfield></datafield></record></collection>